LGND - Ligand Pharmaceuticals Incorporated

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue251,453141,102108,97371,914
Cost of Revenue34,20032,25326,79216,812
Gross Profit217,253108,84982,18155,102
Operating Expenses
Research Development27,86327,86327,86327,863
Selling General and Administrative37,73428,65327,65325,398
Non Recurring----
Others----
Total Operating Expenses87,72673,02665,08844,585
Operating Income or Loss163,72768,07643,88527,329
Income from Continuing Operations
Total Other Income/Expenses Net9,603-10,845-35,9258,000
Earnings Before Interest and Taxes163,72768,07643,88527,329
Interest Expense-48,276-13,460-12,842-11,802
Income Before Tax173,33057,2317,96035,329
Income Tax Expense30,00944,67510,327-192,115
Minority Interest----
Net Income From Continuing Ops143,32112,556-2,367227,444
Non-recurring Events
Discontinued Operations--731731
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income143,32112,556-1,636229,824
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares143,32112,556-1,636229,824